AstraZeneca cancer drug shows encouraging results in phase 1 trial

(marketscreener.com) AstraZeneca PLC on Friday announced that datopotamab deruxtecan has shown "encouraging and durable efficacy" in phase 1 trials.The Cambridge-based pharmaceutical company said that the drug, jointly produced with Daiichi Sankyo Co Ltd, showed positive results in patients with heavily pretreated HR-positive, HER2-low or negative metastatic breast...https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-cancer-drug-shows-encouraging-results-in-phase-1-trial-42511291/?utm_medium=RSS&utm_content=20221209